Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Utilization, Safety, and Related Factors of Illegal Phosphodiesterase Type 5 Inhibitors in South Korean Men

국내 남성에서 포스포디에스테라제 5형 억제제 불법유통 사용현황, 안전성 및 관련 요인

  • Kim, Bong Gi (Korea Institute of Drug Safety and Risk Management) ;
  • Jung, Sun-Young (Korea Institute of Drug Safety and Risk Management) ;
  • Kwon, Kyoung-Eun (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Park, Byung-Joo (Korea Institute of Drug Safety and Risk Management)
  • 김봉기 (한국의약품안전관리원) ;
  • 정선영 (한국의약품안전관리원) ;
  • 권경은 (서울대학교 의과대학 예방의학교실) ;
  • 박병주 (한국의약품안전관리원)
  • Received : 2015.01.15
  • Accepted : 2015.03.13
  • Published : 2015.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Phosphodiesterase Type 5 Inhibitors (PDE5Is), which are prescription drug in South Korea, have been concerned about misuse, overuse and illegal provision of the drugs. This study was performed to investigate utilization and safety of illegal Phosphodiesterase Type 5 Inhibitors (PDE5Is), and related factors among South Korean men. Methods: A questionnaire survey was conducted from May to July in 2013 among 1,500 nationally representative general males using computer-assisted telephone interview (CATI). The questionnaire included the characteristics of population, the characteristics of PDE5Is use, the experience with the use of illegally obtained PDE5Is, and adverse events after PDE5Is use. Results: Among study population, the 1,015 (67.7%) men answered that they have used the illegally obtained PDE5Is. Younger age, single, lower frequency of PDE5Is use in a lifetime was associated with an increased use of illegally obtained PDE5Is. The men experienced adverse events after PDE5Is use is 528 (35.2%). The most common adverse event was mild to moderate hot flashes. Conclusion: We need to enhance awareness about the risk of illegally obtained PDE5Is use, especially in younger men and single. Proactive educations and public relations on safe use of PDE5Is for proper patients are needed.

Keywords

References

  1. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA 1993;270:83-90.
  2. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61. https://doi.org/10.1016/S0022-5347(17)34871-1
  3. Sanchez-Cruz JJ, Cabrera-Leon A, Martín-Morales A, et al. Male erectile dysfunction and health related quality of life. Eur Urol 2003;44:245-53. https://doi.org/10.1016/S0302-2838(03)00215-X
  4. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-4. https://doi.org/10.1056/NEJM199201093260203
  5. Ministry of Food and Drug Safety. Webzine. 2012;Mar+Apr:15-18. Available from: http://www.mfds.go.kr/webzine/201204/ibook_12mar.jsp.
  6. Yang SK. KSSMA eradication campaign for counterfeit PDE5I. Kor J Androl 18th conference 2012.
  7. Kao SL, Chan CL, Tan B, et al. An unusual outbreak of hypoglycemia. N Engl J Med 2009;360:734-6. https://doi.org/10.1056/NEJMc0807678
  8. Department of Health of the Government of the Hong Kong Special Administrative Region. Public urged not to consume capsules for treating sexual dysfunction with undeclared drug. Press Release 2008.
  9. Ministry of Food and Drug Safety. Regulation on potential misuse and abuse drugs. 2014.2.12.
  10. Ministry of Food and Drug Safety. Drug Safety Use Manual 22. Oral Phosphodiesterase Type 5 Inhibitors. 2013.9.4.
  11. Kim MS, Myung SC, Kim SC. Perceptions of Erectile Dysfunction Treatment of Patients Visiting a University Hospital in the Era of Multiple Oral Agents. Kor J Androl 2006;24:18-22.
  12. Jackson G, Montorsi P, Cheitlin MD. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. Urology. 2006;68:47-60. https://doi.org/10.1016/j.urology.2006.05.047
  13. Carson CC, Burnett AL, Levine LA, et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology. 2002;60:12-27.
  14. Banks I, Kirby M, Marfatia A, et al. Assessment, in a General Population of men, of Men's Interaction With the Healthcare System to Obtain Phosphodiesterase Type 5 Inhibitors. Joint Congress of the European and International Societies for Sexual Medicine, December 7-11, Brussels, Belgium, 2008.
  15. Schnetzler G, Banks I, Kirby M, et al. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. J Sex Med 2010;7:1237-46. https://doi.org/10.1111/j.1743-6109.2009.01674.x
  16. Korean Society for Sexual Medicine and Andrology. Fake Phosphodiesterase Type 5 Inhibitors Status. 2012;10:26-29.
  17. Kim SC. Sexual Attitude and Perception on Erectile Dysfunction Treatment among Patients with Erectile Dysfunction and the Patients' Spouses. Korean J Androl 2009;27:1-9.
  18. Micromedex (http://www.micromedexsolutions.com/micromedex2/librarian/)
  19. Yang CS, Kim SC. The Influence of Treatment-emergent Adverse Reactions on Selecting Phosphodiesterase Type 5 Inhibitors. Korean J Urol 2006;47:272-7. https://doi.org/10.4111/kju.2006.47.3.272
  20. Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J Sex Med 2012;9:265-70. https://doi.org/10.1111/j.1743-6109.2011.02537.x
  21. Ministry of Food and Drug Safety. Press Release. 2014.7.31. Available at: http://www.mfds.go.kr/index.do?mid=675&seq=24693.